← Back to search
LOVELACE BIOMEDICAL RESEARCH INSTITUTE
ALBUQUERQUE, NM, 87108
Unclaimed
Prime contracting experience
37 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Prime | Department of Health and Human Services National Institutes of Health | GLP REPEAT DOSE TOXICOLOGY STUDY FOR A LIVE-ATTENUATED RESPIRATORY VIRUS VACCINE. | 75N93021D00031USAspending | $339,534 | Sep 25, 2026 | Sep 28, 2026 – Mar 27, 2027 |
| Prime | Department of Health and Human Services Food and Drug Administration | TASK ORDER 2 - EXAMINING THE INFLUENCE OF SYNTHETIC COOLING AGENTS ON CIGARETTE SENSORY AND SUBJECTIVE EFFECTS AND USE BEHAVIOR | 75F40123D00039USAspending | $1,251,731 | Sep 22, 2026 | Sep 29, 2023 – Sep 29, 2027 |
| Prime | Department of Health and Human Services Food and Drug Administration | NICOTINE FLUX: INVESTIGATING THE IMPACT OF ENDS OUTPUT POWER AND HEATING ELEMENT ON ABUSE LIABILITY | 75F40123D00039USAspending | $3,017,553 | Sep 14, 2026 | Sep 14, 2026 – Sep 13, 2030 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | RTOR BIO-AMT-2312: ASSESSMENT OF THE THERAPEUTIC POTENTIAL OF CHLOROQUINE AND OSELTAMIVIR IN TWO (2) LETHAL MODELS OF INFLUENZA A H5N1 | 75A50122D00021USAspending | $3,723,027 | Aug 21, 2026 | Aug 26, 2026 – Apr 25, 2028 |
| Prime | Department of Health and Human Services National Institutes of Health | CHARACTERIZATION OF A NON-PARALYZING BONT-BASED BIOPHARMACEUTICAL FOR THE TREATMENT OF NEUROPATHIC PAIN | 75N95019D00012USAspending | $1,633,884 | Aug 5, 2026 | Sep 24, 2021 – Jun 30, 2027 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | RADNUC 2201: PERFORMANCE VERIFICATION OF INSTITUTIONAL RADIATION DOSE RESPONSE FOR ACUTE RADIATION SYNDROME (ARS) ANIMAL MODELS (RODENT, RABBIT, MINIPIG, OR NON-HUMAN PRIMATE [NHP]) | 75A50122D00013USAspending | $5,905,018 | Jul 23, 2026 | Sep 29, 2023 – Apr 17, 2027 |
| Prime | Department of Defense Defense Health Agency | LICENSE AND MAINTENANCE SUPPORT, ON-SITE SUPPORT SERVICES FOR VSP WRAIR. | — | $741,851 | Jun 23, 2026 | Sep 16, 2022 – Sep 19, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | EFFICACY AND SAFETY EVALUATION OF LEAD GENE THERAPY CANDIDATE IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT | 75N95019D00012USAspending | $1,899,147 | Jun 22, 2026 | Sep 29, 2023 – Jun 30, 2028 |
| Prime | Department of Health and Human Services Food and Drug Administration | STUDY OF E-CIGARETTE AEROSOL TOXICITY IN IN VIVO NONCLINICAL MODELS. | — | $38,812,829 | Jun 16, 2026 | Sep 26, 2019 – Jun 30, 2025 |
| Prime | Department of Health and Human Services Food and Drug Administration | CTP-2022-111127 - SALTS | HHSF223201710041IUSAspending | $2,130,022 | Jun 1, 2026 | Sep 22, 2022 – Feb 22, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN METHYL MELANOMIC ACIDEMIA (MMAB) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. | 75N95019D00012USAspending | $452,931 | May 29, 2026 | Sep 29, 2021 – May 31, 2026 |
| Prime | Department of Health and Human Services National Institutes of Health | NON-CLINICAL SAFETY ASSESSMENT OF GENE THERAPY (PCCA, MMAB, DOK7 AND COLQ) TO SUPPORT PLATFORM GENE THERAPY FOR CONGENITAL MYASTHENIC DISEASES (DOK7, COLQ) AND ACIDEMIA (PCCA, MMAB) | HHSN271201700017IUSAspending | $5,298,497 | May 29, 2026 | Sep 25, 2020 – May 31, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | THE CONTRACTOR SHALL PERFORM THE TRANSFER, VALIDATION AND QUALIFICATION OF BIOANALYTICAL METHODS FOR DETECTION OF CABOTEGRAVIR AND LEVONORGESTREL IN RAT AND NONHUMAN PRIMATE PLASMA | 75N93022D00001USAspending | $680,219 | Apr 1, 2026 | Nov 15, 2021 – Apr 15, 2026 |
| Prime | Department of Health and Human Services Food and Drug Administration | SOLE SOURCE AWARD OF A 24-MONTH PERIOD, FIRM FIXED PRICE (FFP), ENDS TOXICOLOGICAL STUDIES FOR CENTER FOR TOBACCO PRODUCTS (CTP). | — | $7,058,882 | Sep 19, 2025 | Sep 19, 2025 – Sep 29, 2027 |
| Prime | Department of Health and Human Services National Institutes of Health | TRANSFER AND VALIDATION OF BIOANALYTICAL METHOD FOR DETECTION OF CABOTEGRAVIR IN RAT PLASMA | HHSN272201600009IUSAspending | $255,825 | Jun 20, 2025 | Aug 1, 2019 – Jul 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY/TOXICOLOGY CORE LABORATORY - SCIENTIFIC PROJECT FOR RSA NO. 2057 (RADER) | 75N92019D00017USAspending | $1,609,194 | May 20, 2025 | Sep 8, 2021 – Jun 30, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | GTRP: PHARMACOLOGY/TOXICOLOGY CORE LABORATORY PROJECT FOR RSA NO. 2034 | 75N92019D00017USAspending | $625,344 | May 20, 2025 | Sep 18, 2020 – Apr 30, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | GENE THERAPY RESOURCE PROGRAM (GTRP): PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY | 75N92019D00017USAspending | $1,143,792 | May 20, 2025 | Sep 9, 2022 – Jun 30, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | THE NHLBI REQUIRES THE GENE THERAPY RESOURCE PROGRAM (GTRP) SUPPORT TRANSLATIONAL GENE THERAPY RESEARCH BY PROVIDING RESOURCES AND SERVICES FROM THREE CORE LABORATORIES: 1.) PHARMACOLOGY AND TOXICOLOGY CORE LABORATORY, 2.) PRECLINICAL VECTOR CORE LABORATORY, 3.) CLINICAL COORDINATING CENTER (CCC), WHICH IS NOT REQUIRED TO HAVE ANY LABORATORY CAPABILITIES. | 75N92019D00017USAspending | $507,703 | May 14, 2025 | Dec 19, 2018 – Dec 18, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | EFFICACY AND SAFETY EVALUATION OF A LEAD GENE THERAPY CANDIDATE IN PROPIONIC ACIDEMIA (PA) DISEASE MOUSE MODELS AND BIOANALYTICAL ASSAY METHODS DEVELOPMENT. PERIOD OF PERFORMANCE SEPTEMBER 25, 2020 - SEPTEMBER 24, 2022 | 75N95019D00012USAspending | $2,274,579 | Apr 30, 2025 | Sep 25, 2020 – Jul 15, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | CHARACTERIZATION OF A NON-ADDICTIVE SMALL MOLECULE THERAPEUTICS FOR THE MANAGEMENT OF NON-CANCER PAIN PERIOD OF PERFORMANCE SEPTEMBER 18, 2020 - SEPTEMBER 17, 2022 | 75N95019D00012USAspending | $2,327,263 | Apr 28, 2025 | Sep 18, 2020 – Apr 28, 2025 |
| Prime | Department of Health and Human Services Food and Drug Administration | TASK ORDER 1 -TITLE: ARE REDUCTIONS IN BOE, BOPH, AND OTHER HEALTH RISK MARKERS PROPORTIONAL TO REDUCTIONS IN CIGARETTE SMOKING UPON SWITCHING TO ENDS | 75F40123D00039USAspending | $3,872,713 | Apr 18, 2025 | Sep 27, 2023 – Apr 18, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | NATURAL HISTORY STUDIES IN NEUROMUSCULAR JUNCTION (NMJ) DISEASE MOUSE MODELS. PERIOD OF PERFORMANCE SEPTEMBER 28, 2020 - DECEMBER 31, 2021 | 75N95019D00012USAspending | $2,011,717 | Dec 17, 2024 | Sep 28, 2020 – Jul 31, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | BIOANALYTICAL SUPPORTS FOR A GLP TOX/BIODISTRIBUTION STUDY IN MINI-PIGS | 75N95019D00012USAspending | $792,052 | Dec 17, 2024 | Jun 17, 2022 – Jun 30, 2025 |
| Prime | Department of Health and Human Services National Institutes of Health | CHARACTERIZATION OF A DOWNSTREAM GENE THERAPEUTIC FOR THE REPARATIVE TREATMENT OF SEVERE FRACTURES PERIOD OF PERFORMANCE SEPTEMBER 24, 2020 - NOVEMBER 23, 2021 | 75N95019D00012USAspending | $1,317,349 | Nov 21, 2024 | Sep 22, 2020 – Dec 31, 2024 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | PROJECT RTOR BIO-AMT-1021: DEVELOPMENT OF ANIMAL MODELS FOR EVALUATION OF MEDICAL COUNTERMEASURES FOR SARS-COV-2 | HHSO100201700023IUSAspending | $4,711,753 | Sep 19, 2024 | Mar 30, 2020 – Aug 31, 2021 |
| Prime | Department of Health and Human Services National Institutes of Health | DISEASE MODEL CHARACTERIZATION AND DEVELOPMENT OF ASSAYS TO EVALUATE AND MEASURE PAIN IN A PORCINE MODEL FOR SICKLE CELL DISEASE (SCD) | 75N95019D00012USAspending | $4,969,241 | Jun 28, 2024 | Jul 1, 2019 – Sep 30, 2024 |
| Prime | Department of Health and Human Services National Institutes of Health | EVALUATION OF DRUG EFFICACY IN A RAT MODEL OF NEUROPATHIC PAIN | 75N95019D00012USAspending | $292,814 | Jun 28, 2024 | Sep 24, 2019 – Sep 24, 2020 |
| Prime | Department of Health and Human Services National Institutes of Health | CHARACTERIZATION OF SPONTANEOUS OSTEOGENESIS AFTER SURGICAL SEGMENTAL BONE DEFECT IN A LARGE ANIMAL | 75N95019D00012USAspending | $385,704 | May 8, 2024 | Aug 7, 2023 – Nov 7, 2024 |
| Prime | Department of Defense Department of the Army | IGF::OT::IGF ANIMAL MANAGEMENT SYSTEM SOFTWARE LICENSE/SUPPORT | — | $978,700 | Mar 19, 2024 | Sep 1, 2017 – Aug 31, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | LOVELACE BIOMEDICAL AND ENVIRONMENTAL RESEARCH INSTITUTE: TO PERFORM NON-CLINICAL SAFETY ASSESSMENT OF TTHX1114 TO SUPPORT FUCHS ENDOTHELIAL CORNEAL DYSTROPHY IND APPLICATION. | HHSN271201700017IUSAspending | $2,805,430 | Feb 28, 2024 | Sep 17, 2018 – Oct 30, 2020 |
| Prime | Department of Health and Human Services Office of Assistant Secretary for Preparedness and Response | SUPPORT NON-CLINICAL IMMUNOGENICITY STUDIES OF SARS-COV-2 MICRONEEDLE PATCH VACCINES CANDIDATES IN A SMALL-ANIMAL MODEL | HHSO100201700023IUSAspending | $756,111 | Oct 3, 2023 | Mar 8, 2022 – Dec 7, 2023 |
| Prime | Department of Health and Human Services National Institutes of Health | GLP REPEAT DOSE TOXICOLOGY STUDY FOR BPL-24910 | 75N93021D00031USAspending | $716,374 | Sep 22, 2023 | Sep 26, 2022 – Dec 1, 2023 |
| Prime | Department of Defense Department of the Air Force | COVID-19 THE PURPOSE OF VIDER IS TO UNDERSTAND THE EFFECTIVENESS OF RF DIRECTED ENERGY RADIATION IN REDUCING THE VIABILITY OF VIRAL AEROSOLS WITH THE GOAL OF RAPIDLY DEVELOPING AND DEPLOYING REMEDIATION METHODS FOR SPACES CONTAMINATED WITH SARS-COV-2 | — | $314,575 | Sep 19, 2023 | May 5, 2020 – Dec 29, 2023 |
| Prime | Department of Health and Human Services Food and Drug Administration | IGF::OT::IGF: INVESTIGATE SUBJECTIVE EFFECTS AND NICOTINE PHARMACOKINETICS OF MENTHOLATED SMOKELESS TOBACCO PRODUCTS IN CURRENT USERS | HHSF223201310033IUSAspending | $1,835,595 | Aug 14, 2023 | Sep 20, 2017 – Sep 29, 2022 |
| Prime | Department of Health and Human Services National Institutes of Health | GENE THERAPY RESEARCH PROGRAM (GTRP) - PHARMACOLOGY/TOXICOLOGY CORE LABORATORY: TASK AREA D - RSA NO. 2041 | 75N92019D00017USAspending | $352,485 | May 18, 2023 | Jun 8, 2020 – Nov 19, 2021 |
| Prime | Department of Health and Human Services Food and Drug Administration | IGF::OT::IGF EVALUATION OF E-CIGARETTE AEROSOL IN IN VIVO NONCLINICAL MODELS | HHSF223201510032IUSAspending | $2,472,244 | May 23, 2022 | Aug 14, 2017 – Aug 20, 2022 |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Subcontracting experience
11 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | PO RTI1010373 PO RTI1010373 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541611 Parent award performance state: MD Parent award description: NHLBI CATALYZE PRECLINICAL SERVICES: PROJECTS YR. 4 - TASK ORDER 5 View parent award on USAspending | 75N92022A00005USAspending | $491,392 | Sep 14, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | PO RTI1007276 MOD 1 PO RTI1007276 MOD 1 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541611 Parent award performance state: MD Parent award description: NHLBI CATALYZE PRECLINICAL SERVICES: PROJECTS YR. 4 - TASK ORDER 5 View parent award on USAspending | 75N92022A00005USAspending | $23,924 | Sep 2, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | PO RTI1007276 PO RTI1007276 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541611 Parent award performance state: MD Parent award description: NHLBI CATALYZE PRECLINICAL SERVICES: PROJECTS YR. 4 - TASK ORDER 5 View parent award on USAspending | 75N92022A00005USAspending | $329,781 | May 8, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | CONDUCT A MODEL ESTABLISHMENT STUDY FOLLOWING PARTIAL BODY IRRADIATION WITH G-CSF AND SUPPORTIVE CARE IN RHESUS MONKEYS. PURPOSE OF STUDY IS TO UNDERSTAND THE DOSE RESPONSE RELATIONSHIP (DRR) OF RHESUS NON-HUMAN PRIMATES AFTER A SINGLE DOSE OF RADIATION. PO127420 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: CA Parent award description: ANIMAL MODEL DEVELOPMENT AND EFFICACY TESTING View parent award on USAspending | 75N93020D00011USAspending | $2,023,679 | Mar 2, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | PO RTI1000954 MOD 1 PO RTI1000954 MOD 1 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541611 Parent award performance state: NC Parent award description: NHLBI CATALYZE PROGRAM - PRECLINICAL SERVICES COMPONENT - PROJECTS YEAR 3 View parent award on USAspending | 75N92022A00005USAspending | $49,671 | Jan 26, 2026 | — – — |
| Subcontractor | Department of Health and Human Services | PO RTI1000954 PO RTI1000954 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541611 Parent award performance state: NC Parent award description: NHLBI CATALYZE PROGRAM - PRECLINICAL SERVICES COMPONENT - PROJECTS YEAR 3 View parent award on USAspending | 75N92022A00005USAspending | $956,995 | Aug 22, 2025 | — – — |
| Subcontractor | Department of Health and Human Services | PO C000633721 PO C000633721 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541611 Parent award performance state: NC Parent award description: NHLBI CATALYZE PROGRAM - PRECLINICAL SERVICES COMPONENT - PROJECTS YEAR 3 View parent award on USAspending | 75N92022A00005USAspending | $303,000 | Oct 11, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | PO C000633849 PO C000633849 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541611 Parent award performance state: NC Parent award description: NHLBI CATALYZE PROGRAM - PRECLINICAL SERVICES COMPONENT - PROJECTS YEAR 3 View parent award on USAspending | 75N92022A00005USAspending | $722,956 | Oct 10, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | A 180-DAY MODEL ESTABLISHMENT STUDY FOLLOWING PARTIAL BODY IRRADIATION WITH SUPPORTIVE CARE IN CYNOMOLGUS MONKEYS PO94285 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541715 Parent award performance state: CA Parent award description: ANIMAL MODEL DEVELOPMENT AND EFFICACY TESTING View parent award on USAspending | 75N93020D00011USAspending | $4,323,299 | Jun 26, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | CONDUCT A STUDY TO EVALUATE TEST ARTICLE CONCENTRATION IN SERUM AND BRONCHIAL ALVEOLAR LAVAGE
FLUID (BALF) IN NHPS AT DIFFERENT TIME POINTS FOLLOWING A SINGLE ADMINISTRATION BY INHALATION PO85568 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541714 Parent award performance state: CA Parent award description: NONCLINICAL SERVICES FOR THE DEVELOPMENT OF INTERVENTIONAL AGENTS FOR INFECTIOUS DISEASES View parent award on USAspending | 75N93018D00001USAspending | $166,482 | Dec 19, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | PROJECT TITLE: OUTCOMES OF HUMAN ADENOVIRUS (HADV) INFECTION AND DISEASE IN PEDIATRIC ALLOGENEIC STEM CELL TRANSPLANT RECIPIENTS: A PROSPECTIVE MULTICENTER OBSERVATIONAL COHORT START/END DATES: 07/01/2016 TO 06/30/2021 STUDY SITE: LOVELACE BIOMEDICAL AND ENVIRONMENTAL RESEARCH INSTITUTE (LBERI) STUDY LOCATION: ALBUQUERQUE, NM SITE-PI/STUDY CO-PI NAME: DR. ADRIANA KAJON DR. KAJON WILL SERVE AS THE LBERI SITE-PI AND THE STUDY CO-PI OVERSEEING SPECIMEN SHIPPING FROM CLINICAL SITES AS WELL AS PROCESSING OF ALL RESEARCH-DIRECTED SERUM AND STOOL SPECIMENS, AND SUBSEQUENTLY ALL CLINICAL SPECIMENS POSITIVE FOR ADENOVIRUS BY PCR. DR. KAJON WILL ALSO OVERSEE THE DEVELOPMENT OF THE REDCAPTM DATABASE AND ENSURE THAT THE DATA ARE MAINTAINED IN A MANNER THAT IS COMPLIANT WITH THE NIH REQUIREMENTS FOR THIS CONTRACT. THE DATABASE WILL BE DEVELOPED AND STORED AT LBERI. FINALLY, SHE WILL ASSIST IN PROTOCOL DEVELOPMENT (INCLUDING STUDY DESIGN AND ANALYTIC PLAN), DEVELOPMENT AND MAINTENANCE OF THE MANUAL OF PROCEDURES, AND CONTRIBUTE TO MANUSCRIPT PREPARATION. DATABASE DEVELOPMENT AND MAINTENANCE HANS PETERSEN, SENIOR RESEARCH ASSOCIATE, WILL OVERSEE THE DEVELOPMENT AND MAINTENANCE OF THE REDCAPTM DATABASE. THE DATA ELEMENTS TO BE COLLECTED BY THE CLINICAL SITES WILL BE DETERMINED BY CHOP STUDY PERSONNEL AND SEQUENCED TO MR. PETERSEN FOR DATABASE DEVELOPMENT. THE DATABASE WILL BE DEVELOPED AND PILOTED BEFORE IT IS SHARED WITH CLINICAL SITES FOR ACTUAL DATA ENTRY. WHEN POSSIBLE, THE REDCAPTM DATABASE WILL BE DEVELOPED USING CDISC SDTM TERMINOLOGY. THE LBERI STAFF WILL ASSIST IN REGISTERING ALL LOCAL STUDY STAFF AT EACH OF THE PARTICIPATING CLINICAL SITES FOR REDCAPTM ACCESS. ON A PERIODIC BASIS MR. PETERSEN WILL DOWNLOAD THE DATA AND RUN A NUMBER OF AUTOMATED DATA CHECKS. ANY ERRORS OR MISSING DATA FROM THESE CHECKS WILL BE TRANSFERRED BACK TO THE CLINICAL SITE AND UPDATED. PROCESSING OF RESEARCH SPECIMENS AND CLINICAL SPECIMENS POSITIVE FOR ADENOVIRUS DR. KAJON WILL COMMUNICATE WITH EACH LOCAL SITE€„¢S LABORATORY TO ENSURE APPROPRIATE PROCESSING AND SHIPMENT OF STUDY SPECIMENS. ALL TESTING DICTATED BY THE STUDY PROTOCOL WILL BE PERFORMED IN THE LABORATORY OF DR. ADRIANA KAJON. THIS WILL INCLUDE SEROLOGY TESTING FOR ANTI-ADENOVIRUS IGG BY ELISA, PLAQUE REDUCTION ASSAYS TO DETECT TYPE-SPECIFIC NEUTRALIZING ANTIBODIES, VIRAL ISOLATION IN CELL CULTURE FROM STOOL SPECIMENS, MOLECULAR TYPING OF ADENOVIRUS ISOLATES DETECTED IN RESEARCH AND/OR CLINICAL SPECIMENS OF ENROLLED PATIENTS, AND RESISTANCE TESTING OF ADENOVIRUS TO CIDOFOVIR, AND OTHER ANTIVIRAL AGENTS. CONFERENCE CALLS AND STUDY MEETINGS DR. KAJON AND MR. PETERSEN WILL BE EXPECTED TO PARTICIPATE IN MONTHLY CONFERENCE CALLS. ADDITIONALLY, DR. KAJON WILL BE EXPECTED TO PARTICIPATE IN A STUDY KICK-OFF MEETING, AND IN YEARLY IN-PERSON STUDY MEETINGS. FP00020404_SUB04_06 Parent award context Parent award agency: Department of Health and Human Services · National Institutes of Health Parent award NAICS: 541712 Parent award performance state: PA Parent award description: IGF::OT::IGF - TARGETED CLINICAL RESEARCH TO ADDRESS SELECT VIRAL INFECTIONS View parent award on USAspending | — | $277,484 | Aug 9, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Agencies supported
- Department of Health and Human ServicesGov-sourced
- Department of DefenseGov-sourced